Cardioversion vs. Catheter Ablation for Persistent Atrial Fibrillation
Recruitment status was Recruiting
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
The aim of this randomized study is to evaluate the efficacy of two different approaches for conversion of persistent atrial fibrillation, the non-invasive one (external electrical cardioversion) and the invasive one (catheter ablation).
Condition | Intervention | Phase |
---|---|---|
Atrial Fibrillation |
Procedure: catheter ablation Procedure: external electric cardioversion |
Phase 4 |
Study Type: | Interventional |
Study Design: | Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Parallel Assignment Masking: Open Label Primary Purpose: Treatment |
Official Title: | Randomized Study Comparing Cardioversion vs. Catheter Ablation in Patients With Persistent Atrial Fibrillation |
- Event-free survival after 6 months (i.e. freedom of atrial tachyarrhythmias - as evaluated in a 7-d-holter, stroke, pulmonary vein stenosis - as evaluated in a CT-/MRT-scan 6 months after the initial procedure - and death). [ Time Frame: 6 months ] [ Designated as safety issue: No ]
- success-rate immediately after intervention [ Time Frame: success-rate immediately after intervention ] [ Designated as safety issue: No ]
- need for re-intervention between 2 and 3 months after initial procedure if not stable sinus rhythm at the two-months follow-up (further ablation/cardioversion) [ Time Frame: 2-3 months ] [ Designated as safety issue: No ]
- burden of atrial fibrillation in a 7-day-holter after 6 months [ Time Frame: 6 months ] [ Designated as safety issue: No ]
- significant improvement in exercise capacity (measured by spiroergometry) [ Time Frame: 6 months ] [ Designated as safety issue: No ]
- decrease in NT-pro-BNP levels in the blood after 6 months compared to the level before initial intervention [ Time Frame: 6 months ] [ Designated as safety issue: No ]
- improvement of quality-of-life (combined questionnaire including the SF-36 form) before initial intervention and at the 6-months follow-up [ Time Frame: 6 months ] [ Designated as safety issue: No ]
Estimated Enrollment: | 130 |
Study Start Date: | August 2005 |
Estimated Study Completion Date: | December 2009 |
Estimated Primary Completion Date: | June 2009 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
Experimental: 1
catheter ablation to treat persistent atrial fibrillation
|
Procedure: catheter ablation
catheter ablation to treat persistent atrial fibrillation
|
Experimental: 2
cardioversion and drug prophylaxis to treat persistent atrial fibrillation
|
Procedure: external electric cardioversion
external cardioversion and drug prophylaxis to treat persistent atrial fibrillation
|
Detailed Description:
This randomized study compares two treatment strategies in patients with persistent atrial fibrillation: Cardioversion vs. catheter ablation. Cardioversion is a low risk standard treatment option for patients with persistent atrial fibrillation. However, mid- and long term efficacy (regarding the maintenance of sinus rhythm) is low. Catheter ablation is an invasive treatment which has been reported to result in up to 60-70% of patients in stable sinus rhythm. However, it is a potentially dangerous invasive procedure with potentially fatal complications.
Comparison: External cardioversion vs. catheter ablation
Ages Eligible for Study: | 20 Years to 75 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Age >20 years and <75 years
- documented persistent atrial fibrillation for at least 3 months (documented in at least 2 ECGs or holter-ECGs during the previous 3 months before inclusion and persistent atrial fibrillation in a 7-d-holter)
- documented sufficient anticoagulation for at least 4 weeks before inclusion
Exclusion Criteria:
- Paroxysmal atrial fibrillation
- NYHA IV (if recompensation is not possible)
- Contraindication for warfarin
- Disturbance of blood coagulation
- Myocardial infarction, PTCA/stenting, bypass-operation, stroke, intracranial bleeding less than 3 months before
- Reversible causes of atrial fibrillation (i.e. hyperthyroidism)
- Pregnancy
- LA-diameter > 55mm
- LV-function < 30% EF
- Aortic or mitral stenosis or regurgitation III°-IV°
- Prosthetic valves
Contact: Heidi L Estner, MD | 0049 89 1218 2020 | estner@dhm.mhn.de |
Germany | |
Deutsches Herzzentrum Muenchen | Recruiting |
Munich, Germany, 80636 | |
Contact: Heidi L. Estner, MD 0049 89 1218-2020 estner@dhm.mhn.de | |
Principal Investigator: Heidi L Estner, MD |
Study Chair: | Isabel Deisenhofer, MD | Deutsches Herzzentrum Muenchen |
Principal Investigator: | Heidi L Estner, MD | Deutsches Herzzentrum Muenchen |
No publications provided
Responsible Party: | Prof. A. Schömig, Deutsches Herzzentrum Munich |
ClinicalTrials.gov Identifier: | NCT00196209 History of Changes |
Other Study ID Numbers: | GE IDE No. C00705 |
Study First Received: | September 12, 2005 |
Last Updated: | March 18, 2008 |
Health Authority: | Germany: Federal Institute for Drugs and Medical Devices |
Keywords provided by Deutsches Herzzentrum Muenchen:
atrial fibrillation catheter ablation |
Additional relevant MeSH terms:
Atrial Fibrillation Arrhythmias, Cardiac Heart Diseases Cardiovascular Diseases Pathologic Processes |
ClinicalTrials.gov processed this record on October 16, 2012